Advanced Enzyme Q1 results: Profit, EBITDA slips, company announces share buyback

Advanced Enzymes announced its results for the first quarter of FY2026-27 on Saturday, August 8. The Maharashtra-based company reported a net profit of ₹37 crore, marking a 7.5% decline from the previous financial year's figure of ₹40 crore.

There was some respite in topline numbers, as revenue as the figuer rose 2.2%, increasing to ₹190 crore from ₹186 crore in FY26.

When we look at the profitability aspect of the company's performance, Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) slipped 9.6% YoY. EBITDA declined to ₹51.1 crore from the previous year's ₹56.5 crore.

The margin also slumped, falling to 26.9%, compared to 30.38% (YoY).

The company board also approved the buyback of fully paid-up equity shares having a face value of ₹2/-, with each of the company's equity shares at a price not exceeding ₹500/per equity share ("Maximum Buyback Price") and for an aggregate amount not exceeding ₹697,000,000.

The company also approved the acquisition of the remaining stake of 4.28% Equity Shares from the other existing Shareholders of JC Biotech Private Limited ("JCB") (Existing Subsidiary with 95.72% holding). Furthermore, upon completion of this acquisition, JCB will become a Wholly Owned Subsidiary of the Company.

The shares of Advanced Enzyme Technologies closed lower by 1.79% or ₹5.90. The company shares have risen in value in the past 6 months, with the stock price rising 11.08%, taking the stock price to ₹323.90 per share.